Developing a new treatment for ulcerative colitis that targets the gut
Official title: Predevelopment of VV8220, a Gut-selective CRAC Channel Therapeutic for Ulcerative Colitis
Funded at Vivreon Biosciences, LLC · NIH-11007576 · Data updated 2026-11-12
This study is working on a new medicine to help people with ulcerative colitis by specifically targeting the inflammation in their gut, aiming to provide better relief for those who haven't found success with current treatments.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vivreon Biosciences, LLC NIH-funded |
| Lab location | 1 site (San Diego, UNITED STATES) |
| Project start | May 1, 2022 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $999,997 |
| NIH project number | 2R44AI165096-02 |
| Project ID | NIH-11007576 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with ulcerative colitis who have not responded well to current treatments.
✕Less likely to help
Patients with ulcerative colitis who are already effectively managing their condition with existing therapies may not benefit from this research.
What this research studies
This research focuses on creating a novel therapeutic agent specifically designed to treat ulcerative colitis (UC) by targeting the inflammation in the gut. The approach involves developing a drug that selectively acts on the inner lining of the colon and rectum, where inflammation occurs, while minimizing systemic side effects. By utilizing a mechanism that restricts the action of the drug to the gut, the research aims to improve treatment efficacy for patients who do not respond to existing therapies. The study will explore the role of CRAC channels in gut immune cells to better understand how to control inflammation effectively.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with ulcerative colitis, potentially improving their quality of life.
How similar studies have gone: Other research has shown promise in targeting localized inflammation in various conditions, suggesting that this approach could be effective for ulcerative colitis as well.
Where this research is happening
-
Vivreon Biosciences, LLC
San Diego, United States Active
Researchers
- Principal investigator: Greenberg, Milton L — Vivreon Biosciences, LLC
- Study coordinator: Greenberg, Milton L
Related research
Other NIH-funded projects on the same topics.
-
Outpatient pathway for severe ulcerative colitis in the right care setting
This study tests a safe, outpatient approach using an oral therapy and remote monitoring for people with acute severe ulcerative colitis to avoid hospitalization.
-
Fh15-based therapy to calm inflammation in sepsis and ulcerative colitis
A research project tests a molecule from a parasitic organism (Fh15) to reduce harmful inflammation in adults with sepsis or ulcerative colitis.
-
IMYX-3 treatment for ulcerative colitis
A new therapy approach called IMYX-3 aims to help adults with moderate to severe ulcerative colitis who have not responded well to current treatments.
-
Autoantibodies and ulcerative colitis: how avb6 antibodies may drive disease
This NIH grant aims to understand how antibodies against a gut cell protein (αvβ6) may actively contribute to ulcerative colitis and what that means for future treatments.
-
Selenium supplementation to help moderate-severe ulcerative colitis flare-ups
This grant tests whether giving selenium can help people with moderate to severe ulcerative colitis reduce flares and improve symptoms.
-
Development of TP-317 for Ulcerative Colitis
A new therapy approach for ulcerative colitis aims to repair the intestinal lining and restore immune balance in people with UC, addressing a need for patients who don’t fully respond to current treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.